Immunic FY2025 EPS Boosted by Brookline Capital Management

Immunic, Inc. (NASDAQ:IMUX) – Research analysts at Brookline Capital Management raised their FY2025 EPS estimates for Immunic in a note issued to investors on Tuesday, November 18th. Brookline Capital Management analyst T. Bussian now forecasts that the company will post earnings of ($0.65) per share for the year, up from their prior forecast of ($0.80). The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share. Brookline Capital Management also issued estimates for Immunic’s Q4 2025 earnings at ($0.12) EPS.

Other research analysts also recently issued research reports about the stock. Chardan Capital raised shares of Immunic to a “strong-buy” rating in a research note on Wednesday. Roth Capital assumed coverage on shares of Immunic in a report on Friday, November 7th. They issued a “buy” rating and a $3.00 target price for the company. D. Boral Capital dropped their price target on shares of Immunic from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Thursday, November 13th. HC Wainwright cut their price target on shares of Immunic from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, November 14th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunic in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $7.40.

Immunic Trading Down 0.2%

NASDAQ IMUX opened at $0.69 on Friday. The business’s 50-day moving average price is $0.82 and its 200 day moving average price is $0.85. Immunic has a twelve month low of $0.56 and a twelve month high of $1.42. The company has a market capitalization of $82.56 million, a PE ratio of -0.73 and a beta of 1.53.

Immunic (NASDAQ:IMUX) last announced its earnings results on Thursday, November 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.05.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Focus Partners Wealth grew its stake in Immunic by 19.1% during the first quarter. Focus Partners Wealth now owns 2,583,457 shares of the company’s stock worth $2,816,000 after buying an additional 415,104 shares during the period. Aberdeen Group plc raised its stake in shares of Immunic by 678.1% in the 2nd quarter. Aberdeen Group plc now owns 8,243,941 shares of the company’s stock valued at $5,750,000 after acquiring an additional 7,184,457 shares during the period. 683 Capital Management LLC lifted its holdings in shares of Immunic by 28.6% during the 1st quarter. 683 Capital Management LLC now owns 900,000 shares of the company’s stock valued at $981,000 after acquiring an additional 200,000 shares in the last quarter. Jane Street Group LLC lifted its holdings in shares of Immunic by 279.3% during the 1st quarter. Jane Street Group LLC now owns 207,401 shares of the company’s stock valued at $226,000 after acquiring an additional 152,726 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in Immunic by 5.3% during the 3rd quarter. Vanguard Group Inc. now owns 4,345,105 shares of the company’s stock worth $3,832,000 after purchasing an additional 219,957 shares during the period. Hedge funds and other institutional investors own 51.82% of the company’s stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.